Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Reversible melphalan-induced lung damage

B T Westerfield, J P Michalski, C McCombs

The American Journal of Medicine

|May 1, 1980

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Successful factor XIII treatment of refractory chylothorax in tuberous sclerosis complex-associated lymphangioleiomyomatosis, multifocal multinodular pneumocyte hyperplasia and mediastinal lymphadenopathy.

Lymphology·2018

Same author

Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count).

Canadian respiratory journal·2017

Same author

Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).

Lung·2015

Same author

Research: Why and how to write a paper?

Revista clinica espanola·2015

Same author

Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2012

Same author

Drug-induced eosinophilic pleural effusion.

European respiratory review : an official journal of the European Respiratory Society·2011

Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026

Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026

Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026

Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026

Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026

Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026

See all related articles

Melphalan, a chemotherapy drug, can cause lung damage (pulmonary toxicity), leading to interstitial pneumonitis. This case study documents this rare side effect, highlighting the need for further research into its cause.

Area of Science:

Oncology
Pulmonology
Immunology

Background:

Chemotherapeutic agents are known to cause pulmonary toxicity.
Pulmonary toxicity specifically attributed to melphalan has not been previously documented.

Observation:

A patient developed respiratory symptoms and pulmonary infiltrates twice within two weeks of receiving melphalan and prednisone.
Open lung biopsy confirmed interstitial pneumonitis.
Symptoms resolved upon withholding melphalan.

Findings:

Special studies revealed that the patient's alveolar macrophages suppressed phytohemagglutinin-induced blastogenesis of peripheral lymphocytes.
Melphalan did not directly stimulate lymphocyte blastogenesis.

Implications:

Related Experiment Videos

Melphalan should be recognized as a potential cause of drug-induced pulmonary disease.
The exact pathogenesis of melphalan-induced pulmonary toxicity requires further investigation.